Andrea Boscolo Bragadin

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer

Elisabetta Zulato, Ilaria Attili, Alberto Pavan et al. · British Journal of Cancer · 2020 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti et al. · Translational Lung Cancer Research · 2021 · 44 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

Elisabetta Zulato, Paola Del Bianco, Giorgia Nardo et al. · British Journal of Cancer · 2022 · 22 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer

Andrea Boscolo Bragadin, Paola Del Bianco, Elisabetta Zulato et al. · npj Precision Oncology · 2024 · 15 citations · Full text

Medicine, Immunology, Oncology +17

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors

Giorgia Nardo, Jessica Carlet, Ludovica Marra et al. · Frontiers in Oncology · 2021 · 14 citations · Full text

Medicine, Molecular Genetics, Oncology +17